AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.

AIM ImmunoTech will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 20, 2025, at 2:40 PM ET. The presentation will be led by Thomas Equels, CEO, President, and Executive Vice Chairman. The webinar will be hosted virtually on August 19-21, 2025. AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Inc. (NYSE American: AIM) has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series, focusing on Biotech/MedTech companies. The virtual presentation, scheduled for Wednesday, August 20, 2025, at 2:40 PM ET, will be delivered by Thomas Equels, the company's CEO, President, and Executive Vice Chairman. The webinar is part of a larger virtual conference taking place from August 19-21, 2025.

AIM ImmunoTech is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. The company's lead product, Ampligen® (rintatolimod), is a first-in-class investigational drug that is a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases, and disorders of the immune system.

Webull Financial, the leading online brokerage platform, is committed to empowering self-directed investors with innovative tools and cutting-edge technology. The platform offers low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, providing a seamless and rewarding experience for traders of all levels. Webull Financial is registered with the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC), and is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC).

The webinar will provide an opportunity for investors and financial professionals to learn more about AIM ImmunoTech's research and development efforts, as well as its potential impact on the biotech and medtech industries. The presentation will offer insights into the company's pipeline of therapeutics and its approach to addressing some of the most pressing health challenges of our time.

For more information about AIM ImmunoTech, please visit aimimmuno.com and connect with the company on X, LinkedIn, and Facebook. For more information about Webull Financial, visit www.webull.com.

References:
[1] https://www.stocktitan.net/news/AIM/aim-immuno-tech-to-present-at-the-webull-financial-corporate-connect-vf7ivypja4hj.html
[2] https://www.globenewswire.com/news-release/2025/08/14/3133503/29489/en/AIM-ImmunoTech-to-Present-at-the-Webull-Financial-Corporate-Connect-Webinar-Series-Biotech-MedTech.html